DYNE THERAPEUTICS INC (DYN)
US26818M1080 - Common Stock
ChartMill assigns a Buy % Consensus number of 88% to DYN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 38.51. This target is 51.36% above the current price.
DYN was analyzed by 13 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about DYN.
In the previous month the buy percentage consensus was at a similar level.
DYN was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-26 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-03-07 | Guggenheim | Maintains | Buy -> Buy |
| 2024-03-06 | Stifel | Maintains | Buy -> Buy |
| 2024-03-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-03-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-05 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-02-20 | HC Wainwright & Co. | Initiate | Buy |
| 2024-01-04 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2023-08-09 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023-08-04 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-03-03 | Chardan Capital | Maintains | Buy |
| 2023-02-27 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2023-02-15 | Oppenheimer | Initiate | Outperform |
| 2023-01-26 | Guggenheim | Initiate | Buy |
| 2022-11-29 | JP Morgan | Maintains | Overweight |
| 2022-11-04 | Raymond James | Maintains | Outperform |
| 2022-07-20 | Chardan Capital | Initiate | Buy |
| 2022-07-12 | Raymond James | Initiate | Outperform |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |